Table 2.
Disease-modifying treatments (DMTs) pretreatment.
| DMT pre-treatment |
Total (N = 883)
n (%) |
|---|---|
| Total | 727 (82.3) |
| Interferon-beta | 463 (52.4) |
| Fingolimod | 311 (35.2) |
| Natalizumab | 308 (34.9) |
| Glatiramer acetate | 255 (28.9) |
| Othera | 131 (14.8) |
| Dimethyl fumarate | 109 (12.3) |
| Teriflunomide | 44 (5.0) |
| Mitoxantrone | 18 (2.0) |
| Azathioprine | 9 (1.0) |
| Unknown | 5 (0.6) |
| Methotrexate | 2 (0.2) |
| Rituximab | 1 (0.1) |
Values are n and percentages of total.
a
“Other” includes unspecified drugs in 31 patients, daclizumab in 20 patients, immunoglobulins in six patients, and a variety of other drugs in the remaining patients.